Comparison of three dose regimens of aprotinin in infants undergoing the arterial switch operation

Annals of Cardiac Anaesthesia

Volumn 13, Issue 2, 2010, Pages 110-115

  Verma, Yashwant S ^a   Chauhan, Sandeep ^a   Bisoi, Akshay K ^a   Gharde, Parag ^a   Kiran, Usha ^a   Das, Sambhu N ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Aprotinin; Infants; Postoperative bleeding; Transposition of great arteries

Indexed keywords

APROTININ; CREATININE; FIBRINOGEN; PROTAMINE; UREA; HEMOSTATIC AGENT;

ANESTHESIA INDUCTION; ARTERY BYPASS; ARTICLE; BLOOD CLOTTING TIME; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CHILD HEALTH CARE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; ERYTHROCYTE CONCENTRATE; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; GREAT VESSELS TRANSPOSITION; HEMATOCRIT; HUMAN; INFANT; INTERNATIONAL NORMALIZED RATIO; KIDNEY FUNCTION; KIDNEY FUNCTION TEST; MALE; NEWBORN; PEDIATRIC INTENSIVE CARE NURSING; PEDIATRIC SURGERY; POSTOPERATIVE CARE; POSTOPERATIVE HEMORRHAGE; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SURGICAL DRAINAGE; THROMBOCYTE COUNT; THROMBOCYTE PRESERVATION; UREA BLOOD LEVEL; URINE VOLUME; WEANING; BLOOD CLOTTING TEST; COMPARATIVE STUDY; ERYTHROCYTE TRANSFUSION; TRANSPOSITION OF GREAT VESSELS; TREATMENT OUTCOME; UTILIZATION;

APROTININ; BLOOD COAGULATION TESTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROCYTE TRANSFUSION; FEMALE; HEMOSTATICS; HUMANS; INFANT; INFANT, NEWBORN; MALE; POSTOPERATIVE HEMORRHAGE; TRANSPOSITION OF GREAT VESSELS; TREATMENT OUTCOME;

EID: 77955912112     PISSN: 09719784     EISSN: 09745181     Source Type: Journal    
DOI: 10.4103/0971-9784.62935     Document Type: Article

References (29)

1. Kern FH, Morana MJ, Sears JJ, Hickey PR. Coagulation defects in neonates undergoing cardiopulmonary bypass. Ann Thorac Surg 1992;54:541-6.
2. Guay J, Rivard GE. Mediastinal bleeding after cardiopulmonary bypass in pediatric patients. Ann Thorac Surg 1996;62:1955-60.
3. Murkin JK. Cardiopulmonary bypass and the inflammatory response: A role for serine protease inhibitors? J Cardiothorac Vasc Anesth 1997;11:19-23.
4. Campbell DJ, Dixon B, Kladis A, Kemme M, Santamaria JD. Activation of the Kallikrein-Kinin system by cardiopulmonary bypass in humans. Am J Physiol Regul Integr Comp Physiol 2001;281:R1059-70.
5. Butler J, Parker D, Pillai R, Westaby S, Shale DJ, Rocker GM. Effect of cardiopulmonary bypass on systemic release of neutrophil elastase and tumor necrosis factor. J Thorac Cardiovasc Surg 1993;105:25-30.
6. Emerson TE. Pharmacology of aprotinin and efficacy during cardiopulmonary bypass. Cardiovasc Drug Rev 1989;7:127-40.
7. Hill GE, Alonso A, Spurzem JR, Stammers AH, Robins RA. Aprotinin and methylprednisolone equally blunt cardiopulmonary bypass-induced inflammation in humans. J Thorac Cardiovasc Surg 1995;110:1658-62.
8. Karkouti K, Beattie WS, Dattilo KM, McCluskey SA, Ghannam M, Hamdy A, et al. A propensity score case-control comparision of aprotinin and tranexamic acid in high -transfusion- risk cardiac surgery. Transfusion 2006;46:327-38.
9. Mangano DT, Tudor IC, Dietizel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006;354:353-65.
10. Murugesan C, Banakal SK, Garg R, Keshavamurthy S, Muralidhar K. The efficacy of aprotinin in arterial switch operations in infants. Anesth Analg 2008;107:783-7
11. Boldt J, Knothe C, Zickmann B. Aprotinin in pediatric cardiac operations: Platelet function, blood loss, and use of homologous blood. Ann Thorac Surg 1993;55:1460-6.
12. Herynkopf F, Lucchese F, Pereira E. Aprotinin in children undergoing correction of congenital heart defects: A double blind pilot study. J Thorac Cardiovasc Surg 1994;108:517-21.
13. Miller BE, Tosone SR, Tam VK. Hematologic and economic impact of aprotinin in reoperative pediatric cardiac operations. Ann Thorac Surg 1998;66:535-41.
14. Mossinger H, Dietrich W. Activation of hemostasis during cardiopulmonary bypass and pediatric aprotinin dosage. Ann Thorac Surg 1998;65:45-50.
15. Tempe DK, Virmani S. Coagulation abnormalities in patients with cyanotic congenital heart disease. J Cardiothorac Vasc Anesth 2002;16:752-65.
16. Goldschmidt B, Sarkadi B, Gardos G, Matlary A. Platelet production and survival in cyanotic congenital heart disease. Scand J Haematol 1974;13:110-75.
17. Gill JC, Wilsin AD, Endres-Brooks J, Montgomery RR. Loss of the largest von willebrand factor multimers from the plasma of patients with congenital cardiac defects. Blood 1986;67:758-61.
18. Dennis LH, Stewart JL, Conrad ME. Heparin treatment of haemorrhagic diathesis in cyanotic congenital heart disease. Lancet 1967;1:1088-9.
19. Stammers AH, Rauch ED, Willett LD, Newberry JW, Duncan KF. Pre- operative coagulopathy management of a neonate with complex congenital heart disease: A case study. Perfusion 2000;15:161-8.
20. Brodsky I, Gill DN, Lusch CJ. Fibrinolysis in congenital heart disease: Preoperative treatment with epsilon-aminocaproic acid. Am J Clin Pathol 1969;51:51-7.
21. Reid RW, Zimmerman AA, Laussen PC, Mayer JE, Gorlin JB, Burrows FA. The efficacy of tranexamic acid versus placebo in decreasing blood loss in pediatric patients undergoing repeat cardiac surgery. Anesth Analog 1997;84:990-6.
22. Chauhan S, Bisoi A, Kumar N, Mittal D, Kale S, Kiran U, et al. Dose comparision of tranexamic acid in pediatric cardiac surgery. Asian Cardiovasc Thorac Ann 2004;12;121-4.
23. Chauhan S, Das SN, Bisoi A, Kale S, Kiran U. Comparison of epsilon aminocaproic acid and tranexamic acid in pedriatic cardiac surgery. J Cardiothorac Vasc Anesth 2004;18:141-3.
24. Chauhan S, Kumar BA, Rao BH, Rao MS, Dubey B, Saxena N, et al. Efficacy of aprotinin, epsilon aminocaproic acid, or combination in cyanotic heart disease. Ann Thorac Surg 2000;70:1308-12.
25. Eaton MP. Antifibrinolytic therapy in surgery for congenital heart disease. Anesth Analg 2008;106:1087-100.
26. Dietrich W, Ebell A, Busley R, Boulesteix AL. Aprotinin and anaphylaxis: Analysis of 12,403 exposures to aprotinin in cardiac surgery. Ann Thorac Surg 2007;84:1144-50.
27. Jaquiss RD, Ghanayem NS, Zacharisen MC, Mussatto KA, Tweddell JS, Litwin SB. Safety of aprotinin use and reuse in pediatric cardiothoracic surgery. Circulation 2002;106:190-4.
28. D'Errico CC, Shayevitz JR, Martindale SJ. The efficacy and cost of aprotinin in children undergoing reoperative open heart surgery. Anesth Analg 1996;83:1193-9.
29. Carrel TP, Schwanda M, Vogt PR, Turina MI. Aprotinin in pediatric cardiac operations: A benefit in complex malformations and with high dose regimen only. Ann Thorac Surg 1998;66;153-8.